TY  - GEN
N2  - This piece discusses pharmaceutical product reformulations and product hopping strategies, along with the impact that antitrust scrutiny may have on innovation incentives. The main thesis presented is that for the sake of preserving innovation incentives, antitrust analysis should not focus on whether the innovation examined is deemed as an “incremental” one according to antitrust enforcers; on the contrary, the overall economic and strategic context of the product reformulation should play the central role in the case-by-case antitrust analysis.
AB  - This piece discusses pharmaceutical product reformulations and product hopping strategies, along with the impact that antitrust scrutiny may have on innovation incentives. The main thesis presented is that for the sake of preserving innovation incentives, antitrust analysis should not focus on whether the innovation examined is deemed as an “incremental” one according to antitrust enforcers; on the contrary, the overall economic and strategic context of the product reformulation should play the central role in the case-by-case antitrust analysis.
T1  - Rethinking Pharmaceutical Product Reformulations
AU  - Athanasiadou, Amalia
LA  - eng
ID  - 42098
KW  - Product reformulations
KW  - Antitrust
KW  - Generic entry
KW  - Innovation
KW  - Pharmaceuticals
TI  - Rethinking Pharmaceutical Product Reformulations
LK  - https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3612699
UR  - https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3612699
ER  -